How Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG Biomarker

In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, beginning with binge eating disorder. The discussion also covers Entropy’s work on real‑time EEG and brain entropy as a potential biomarker, the company’s financing,  regulatory roadmap, and longer‑term expansion opportunities in areas such as PTSD.